| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -66.2 | -61.5 |
| EPS (diluted, $ a share) | $-1.05 | $-1.16 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: KOD. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Kodiak Sciences Inc.: key numbers
- Share price
- $100.73Close, Nov 16
- Market cap
- $6.59B
- Shares outstanding
- 65.4MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Kodiak Sciences Inc.
All →Kodiak Sciences Financial Results
Kodiak Sciences reported Q3 2026 financial results and provided updates on its late-stage retinal pipeline, including positive Phase 3 DAYBREAK results for Zenkuda and tabirafusp-ted. The company plans to submit a multi-indication BLA for Zenkuda by the end of 2026 and expects pivotal data for KSI-101 in December 2026.
“We believe Kodiak stands apart in retina, with three late-stage assets that together give us the opportunity to build a leading retinal medicines company.”
Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences
“Looking ahead, we expect to announce the first Phase 3 KSI-101 results in December and, if successful, plan to file a BLA for KSI-101 in the second quarter of 2027. We are also on track to submit the multi-indication BLA for Zenkuda by year end, supported by five successful Phase 3 studies.”
Victor Perlroth, M.D., Chief Executive Officer of Kodiak Sciences
Kodiak Sciences Director Baker Bros. Advisors LP Buys $24.3M of Stock
Baker Bros. Advisors LP, Director, bought 247,090 shares of Kodiak Sciences Inc. at $98.51 a share, worth $24.3M in total between Nov 4, 2026 and Nov 5, 2026. Shares held after the trade: 20,424,859 (+0.4%).
- Value
- $24.3M
- Shares
- 247,090
- Average price
- $98.51
- Role
- Director
- Holding change
- +0.4%
- Trade date
- Nov 4, 2026 to Nov 5, 2026
Kodiak Sciences CFO John A. Borgeson Sells $2.69M of Stock
John A. Borgeson, CFO, sold 29,900 shares of Kodiak Sciences Inc. at $87.67 to $93.71 a share (average $89.99) in 7 transactions, worth $2.69M in total on Oct 21, 2026. Shares held after the trade: 212,030 (-0.9%).
- Value
- $2.69M
- Shares
- 29,900
- Average price
- $89.99
- Role
- CFO
- Holding change
- -0.9%
- Trade date
- Oct 21, 2026
Kodiak Sciences Director Baker Bros. Advisors LP Buys $63.4M of Stock
Baker Bros. Advisors LP, Director, bought 715,508 shares of Kodiak Sciences Inc. at $84.24 to $89.86 a share (average $88.59) in 21 transactions, worth $63.4M in total between Sep 28, 2026 and Sep 29, 2026. Shares held after the trade: 19,772,333 (+0.5%).
- Value
- $63.4M
- Shares
- 715,508
- Average price
- $88.59
- Role
- Director
- Holding change
- +0.5%
- Trade date
- Sep 28, 2026 to Sep 29, 2026
Kodiak Sciences Director Baker Bros. Advisors LP Buys $34.9M of Stock
Baker Bros. Advisors LP, Director, bought 418,105 shares of Kodiak Sciences Inc. at $79.40 to $85.97 a share (average $83.58) in 26 transactions, worth $34.9M in total on Sep 28, 2026. Shares held after the trade: 19,153,010 (+0.0%).
- Value
- $34.9M
- Shares
- 418,105
- Average price
- $83.58
- Role
- Director
- Holding change
- +0.0%
- Trade date
- Sep 28, 2026
Kodiak Sciences Director Baker Bros. Advisors LP Buys $58.6M of Stock
Baker Bros. Advisors LP, Director, bought 807,840 shares of Kodiak Sciences Inc. at $61.21 to $78.57 a share (average $72.57) in 30 transactions, worth $58.6M in total on Sep 28, 2026. Shares held after the trade: 18,435,276 (+0.0%).
- Value
- $58.6M
- Shares
- 807,840
- Average price
- $72.57
- Role
- Director
- Holding change
- +0.0%
- Trade date
- Sep 28, 2026